Bristol Myers Squibb has received the FDA’s green light to introduce another immunotherapy-based treatment in first-line ...

The European Commission (EC) has granted approval for AstraZeneca's Imfinzi plus chemotherapy for treating resectable ...

AstraZeneca saw 18% revenue growth in 2024, boosted by key drugs and global innovation. See here to know why we recommend a ...

AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), a pharmaceutical giant with a market capitalization of $223 billion and an impressive 82% gross profit margin according to InvestingPro, announced today that ...

Imfinzi in combination with chemotherapy has been approved in the European Union, EU, for the treatment of adults with ...

The Cambridge, England-based pharmaceuticals firm said Enhertu, or trastuzumab deruxtecan, has been approved in the EU as a therapy for adult patients with unresectable or metastatic hormone ...

Meanwhile, the FDA has approved AstraZeneca’s Imfinzi as a perioperative treatment for muscle-invasive bladder cancer, marking it as the first immunotherapy for this condition. This approval was ...

After Meritain rejected the initial immunotherapy drug, Imfinzi, Brian applied for coverage of a second, similar drug, ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

AstraZeneca AZN announced that the FDA has approved its blockbuster drug, Imfinzi (durvalumab), for a bladder cancer indication in the United States. Imfinzi is approved in combination with ...

AstraZeneca’s Imfinzi (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy after radical cystectomy (surgery to remove the ...